ReCor completes enrollment in PARADISE system clinical study for 'resistant' hypertension

May 14 2012

ReCor Medical, an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pilot clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with 'resistant' hypertension ("HTN"), a major risk factor for cardiovascular disease.    

Current results of the study will be presented from the podium on Thursday, May 17, 08:00-10:20, Room 241, Palais des Congres, by principal investigator Thomas A. Mabin, M.D., Vergelegen Medi-Clinic, South Africa.

Preliminary clinical data for PARADISE were previously reported by Dr. Mabin at the recent "TRenD 2012" transcatheter renal denervation scientific meeting. The PARADISE data showed that systolic blood pressure was reduced by an average of 31 mm Hg in 7 patients at 60-days follow-up. The scientific literature demonstrates that only a 5 mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

"ReCor's PARADISE system is designed to provide a minimally invasive ultrasound therapy to resistant hypertension patients to help reduce their blood pressure," said Mano Iyer, President & CEO, ReCor Medical. "In the REDUCE study, we have been able to show that our novel PARADISE^TM system is capable of safely and quickly denervating patients, resulting in sustained blood pressure reductions out to 6 months. We look forward to Dr. Mabin's reporting of the current results of our REDUCE pilot clinical trial at PCR as we move forward with our launch of our PARADISE^TM system in Europe."